Should a pituitary magnetic resonance imaging be ordered for a 51‑year‑old man with low serum testosterone (≈189 ng/dL) and low follicle‑stimulating hormone (≈1.7 mIU/mL)?

Should You Order a Pituitary MRI?

Yes, you should order a pituitary MRI for this 51-year-old man with testosterone of 189 ng/dL and FSH of 1.7 mIU/mL, as he has confirmed secondary hypogonadism with low gonadotropins that warrants evaluation for hypothalamic-pituitary pathology.

Rationale for Imaging

This patient clearly has secondary (hypogonadotropic) hypogonadism based on:

• Low testosterone (189 ng/dL, which is <300 ng/dL) 1
• Inappropriately low/normal FSH (1.7 mIU/mL) that should be elevated if the testes were the primary problem 1

The Endocrine Society guidelines specifically recommend evaluating men with secondary hypogonadism for pituitary and hypothalamic disorders through imaging and additional testing 1.

When to Image: Evidence-Based Thresholds

The diagnostic yield of pituitary MRI improves significantly when specific criteria are met 1:

High-Priority Imaging Criteria (from guidelines):

• Testosterone <150 ng/dL (5.2 nmol/L) 1
• Pan-hypopituitarism 1
• Persistent hyperprolactinemia 1
• Symptoms of mass effect (visual changes, new headaches) 1

Your Patient's Status:

While your patient's testosterone of 189 ng/dL is above the strict 150 ng/dL threshold, recent research provides more nuanced guidance 2, 3:

• A 2021 study identified testosterone ≤6.1 nmol/L (≈176 ng/dL) or LH ≤1.9 U/L as validated predictors of structural pituitary abnormalities 2
• Your patient's testosterone of 189 ng/dL is borderline close to this threshold
• The FSH of 1.7 is notably suppressed, suggesting significant hypothalamic-pituitary dysfunction 1

Additional Workup Required Before or With MRI

Before proceeding with MRI, you must obtain 1:

• Serum prolactin - elevated prolactin (>2× upper limit of normal) strongly predicts adenomas and is found in 75% of pituitary adenomas in hypogonadal men 4
• Iron saturation/ferritin - to exclude hemochromatosis 1
• Anterior pituitary function testing if clinically indicated - to assess for other hormone deficiencies 1

Prevalence of Findings

What imaging typically reveals in men with secondary hypogonadism 5:

• Normal pituitary: 83.6% 5
• Microadenomas: 8.5% 5
• Macroadenomas: 1.8% 5
• Other abnormalities (empty sella, cysts): 5.7% 5

Critical point: Current Endocrine Society guidelines would have missed imaging in 50% of patients with significant pituitary pathology in one study 5, suggesting the 150 ng/dL threshold may be too restrictive.

Clinical Decision Algorithm

Order MRI if ANY of the following:

1. Testosterone <150 ng/dL 1
2. Prolactin >2× upper limit of normal 4, 6
3. Evidence of other pituitary hormone deficiencies 1
4. Visual symptoms or headaches 1
5. Testosterone 150-200 ng/dL with very low gonadotropins (LH or FSH <2) 2 - your patient falls here

Common Pitfalls to Avoid

• Don't test testosterone during acute illness - systemic illness suppresses the hypothalamic-pituitary-gonadal axis and causes functional hypogonadism 1, 7
• Ensure morning testing (before 10 AM, fasting) - testosterone has circadian variation 7
• Stop biotin supplements 72 hours before testing - biotin interferes with LH/FSH assays 1
• Check for reversible causes first: obesity, opioid use, glucocorticoids, sleep apnea 1
• Don't rely solely on testosterone thresholds - the combination of very low gonadotropins with low-normal testosterone increases pretest probability of pathology 2, 3

Why This Matters for Your Patient

Identifying secondary hypogonadism has critical therapeutic implications 1:

• Fertility can potentially be restored with gonadotropin therapy (not possible in primary hypogonadism) 1
• Underlying pituitary tumors require specific management beyond testosterone replacement 1
• Other pituitary hormone deficiencies may be present and need treatment 1
• Functional causes (obesity, medications) may be reversible 1

Given your patient's combination of low testosterone (189 ng/dL) and suppressed FSH (1.7), the risk-benefit analysis favors imaging to exclude structural pathology, particularly after obtaining prolactin levels.